Oncolytics Biotech Inc (ONC)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Oncolytics Biotech Inc (ONC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014332
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oncolytics Biotech Inc (Oncolytics) is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company’s lead product, Reolysin, a formulation of the human reovirus, is at Phase II clinical trials indicated for the treatment of lung, ovarian, colorectal, pancreatic, prostate, breast, head and neck cancers. Reolysin is also undergoing various other clinical trials to determine its use in other types of cancer, such as for squamous cell carcinoma, metastatic colorectal cancer, metastatic melanoma trial, and non-small cell lung cancer. The company and its partners are conducting clinical trials in several countries across the world, including Canada and the US. Oncolytics is headquartered in Calgary, Alberta, Canada.

Oncolytics Biotech Inc (ONC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Oncolytics Biotech Inc, Medical Devices Deals, 2011 to YTD 2017 9
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Oncolytics Biotech Enters into Licensing Agreement with Adlai Nortye Biopharma 11
Equity Offering 12
Oncolytics Biotech Raises USD8.5 Million in Public Offering of Units 12
Oncolytics Biotech to Raise USD20 Million in Public Offering of Common Stock 14
Oncolytics Biotech Completes First Tranche Of Private Placement Of Shares For US$1 Million 15
Oncolytics Biotech Completes Public Offering Of Common Stock For US$32 Million 16
Oncolytics Biotech Completes Private Placement Of Shares For US$21 Million 17
Oncolytics Biotech Raises US$7.87 Million Upon Exercise Of Warrants 19
Oncolytics Biotech Raises US$6.8 Million Upon Exercise Of Warrants 20
Oncolytics Biotech Inc – Key Competitors 21
Oncolytics Biotech Inc – Key Employees 22
Oncolytics Biotech Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Strategy And Business Planning 24
Jun 27, 2017: Oncolytics Biotech Opens U.S. Based Office in San Diego 24
Financial Announcements 25
Nov 08, 2017: Oncolytics Biotech Announces 2017 Third Quarter Results 25
Aug 03, 2017: Oncolytics Biotech Announces 2017 Second Quarter Results 26
May 05, 2017: Oncolytics Biotech Announces 2017 First Quarter Results 27
Mar 10, 2017: Oncolytics Biotech Announces 2016 Year-End Results 28
Nov 03, 2016: Oncolytics Biotech Announces 2016 Third Quarter Results 29
Aug 04, 2016: Oncolytics Biotech Announces 2016 Second Quarter Results 30
May 06, 2016: Oncolytics Biotech Announces 2016 First Quarter Results 31
Mar 11, 2016: Oncolytics Biotech Announces 2015 Year End Results 32
Corporate Communications 34
Jun 29, 2017: Oncolytics Biotech Appoints Andrew de Guttadauro, President of Oncolytics Biotech 34
Jan 19, 2017: Oncolytics Biotech Appoints Dr. Matt Coffey to the Role of President and CEO 35
Dec 06, 2016: Oncolytics Biotech announces resignation of board member 36
Nov 10, 2016: Oncolytics Biotech Announces Appointment of New Chief Medical Officer 37
Nov 02, 2016: Oncolytics Biotech Announces Management Team Changes 38
Mar 24, 2016: Oncolytics Biotech Announces Filing of Management Information Circular and Details of 2016 Annual General Meeting 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oncolytics Biotech Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Oncolytics Biotech Inc, Medical Devices Deals, 2011 to YTD 2017 9
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Oncolytics Biotech Enters into Licensing Agreement with Adlai Nortye Biopharma 11
Oncolytics Biotech Raises USD8.5 Million in Public Offering of Units 12
Oncolytics Biotech to Raise USD20 Million in Public Offering of Common Stock 14
Oncolytics Biotech Completes First Tranche Of Private Placement Of Shares For US$1 Million 15
Oncolytics Biotech Completes Public Offering Of Common Stock For US$32 Million 16
Oncolytics Biotech Completes Private Placement Of Shares For US$21 Million 17
Oncolytics Biotech Raises US$7.87 Million Upon Exercise Of Warrants 19
Oncolytics Biotech Raises US$6.8 Million Upon Exercise Of Warrants 20
Oncolytics Biotech Inc, Key Competitors 21
Oncolytics Biotech Inc, Key Employees 22
Oncolytics Biotech Inc, Subsidiaries 23

★海外企業調査レポート[Oncolytics Biotech Inc (ONC)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Terma AS:企業の戦略・SWOT・財務情報
    Terma AS - Strategy, SWOT and Corporate Finance Report Summary Terma AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Liechtensteinische Landesbank Private Clients:企業の戦略・SWOT・財務情報
    Liechtensteinische Landesbank Private Clients - Strategy, SWOT and Corporate Finance Report Summary Liechtensteinische Landesbank Private Clients - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • Altimmune Inc (ALT):製薬・医療:M&Aディール及び事業提携情報
    Summary Altimmune Inc (Altimmune), formerly Vaxin Inc is an immunotherapeutics company that develops vaccines and other biological products. The company’s products include nasovax, an intranasally administered recombinant influenza vaccine; and heptcell, an immunotherapy for patients chronically inf …
  • The Hong Kong and China Gas Company Limited:企業の戦略・SWOT・財務分析
    The Hong Kong and China Gas Company Limited - Strategy, SWOT and Corporate Finance Report Summary The Hong Kong and China Gas Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Guangzhou Institute of Biomedicine and Health-製薬・医療分野:企業M&A・提携分析
    Summary Guangzhou Institute of Biomedicine and Health (GIBH) is a research institute that conducts research on stem cell and regenerative medicine, chemical biology, infection and immunity, public health and scientific research equipment development. The institute’s life process and disease mechanis …
  • GS Energy Corp-エネルギー分野:企業M&A・提携分析
    Summary GS Energy Corp (GS Energy) is an energy holding company that manufactures and markets transportation fuels. The company's services include exploration and production, green growth, gas and electric power, refining and petrochemicals. It's refining and petrochemicals services comprise manufac …
  • GW Pharmaceuticals Plc (GWPH):製薬・医療:M&Aディール及び事業提携情報
    Summary GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the …
  • LSIS Co Ltd (010120):企業の財務・戦略的SWOT分析
    LSIS Co Ltd (010120) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Axalta Coating Systems Ltd:企業の戦略・SWOT・財務情報
    Axalta Coating Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary Axalta Coating Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Cedars-Sinai Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary Cedars-Sinai Medical Center (Cedars-Sinai), formerly Kaspare Cohn Hospital is an academic and medical center that provides healthcare services for patients and medical professionals, and research and education services. The center offers treatments for various conditions such as abdominal pa …
  • Emerald Health Therapeutics Inc (EMH):製薬・医療:M&Aディール及び事業提携情報
    Summary Emerald Health Therapeutics Inc (Emerald Health), formerly T-Bird Pharma Inc, is a producer of pharmaceutical grade medical cannabis. The company extracts and markets dried cannabis, and cannabis oils and capsules. It offers cannabinoid medicines, which are present in an unparalleled opportu …
  • Lidds AB (LIDDS):製薬・医療:M&Aディール及び事業提携情報
    Summary Lidds AB (Lidds) is a developer of pharmaceutical products for the treatment of cancer and other diseases. The company offers Liproca Depot, an injectable product used for the treatment of prostate cancer. Its Liproca is a bioresorbable, biocompatible and locally injectable modified release …
  • Clalit Health Services:企業の戦略的SWOT分析
    Clalit Health Services - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Statnett SF-エネルギー分野:企業M&A・提携分析
    Summary Statnett SF (Statnett) transmits and distributes high voltage electricity in Norway primarily generated from its hydro-electric power plants. It operates as a system operator in the Norwegian energy system. The company is a state enterprise, established under the Act relating to state-owned …
  • VAALCO Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    VAALCO Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary VAALCO Energy, Inc. (VAALCO) is an upstream oil and gas company. It acquires, explores, develops and produces crude oil and natural gas from assets. The company conducts the exploration activities …
  • MYR Group Inc (MYRG):企業の財務・戦略的SWOT分析
    Summary MYR Group Inc (MYR Group) is an electrical contractor that provides specialty contracting services for industrial, commercial, and electrical infrastructure markets. The company operates substations, transmission lines, and distribution systems. It offers services such as distribution constr …
  • Civitas Solutions Inc:企業の戦略・SWOT・財務情報
    Civitas Solutions Inc - Strategy, SWOT and Corporate Finance Report Summary Civitas Solutions Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Ryanair Holdings plc (RY4C):企業の財務・戦略的SWOT分析
    Ryanair Holdings plc (RY4C) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Chiome Bioscience Inc (4583):製薬・医療:M&Aディール及び事業提携情報
    Summary Chiome Bioscience Inc (Chiome Bioscience) is a healthcare service company that provides research and development of therapies. The company research and develops antibody drugs for the treatment of autoimmune and inflammatory diseases. Its ADLib system is a monoclonal antibody generating syst …
  • Societe Des Bains De Mer Sa
    Societe Des Bains De Mer Sa - Strategy, SWOT and Corporate Finance Report Summary Societe Des Bains De Mer Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆